Skip to main content
. Author manuscript; available in PMC: 2019 Jan 15.
Published in final edited form as: Mol Pharm. 2017 Nov 22;14(12):4628–4635. doi: 10.1021/acs.molpharmaceut.7b00731

Figure 4.

Figure 4.

GFP fluorescence imaging in response to NIR-PIT. (A) NIR-PIT outline. GFP fluorescence images were scanned at each time point as shown. (B) GFP fluorescence real-time images of A431-luc-GFP tumor bearing mice for NIR-PIT. Yellow arrows indicate the tumor. GFP fluorescence intensity showed almost no change in the early phase (0, 10, 20, 30 min later) after NIR-PIT. GFP fluorescence intensity in the late phase (24 and 48 h later) was greatly lower than that before NIR-PIT. (C) Comparison of GFP fluorescence intensity in A431-luc-GFP tumor bearing mice between non-PIT and NIR-PIT treated groups. %TBRGFP 24 and 48 h after NIR-PIT showed significantly lower intensity in non-PIT group than in NIR-PIT treated group (*p < 0.05, vs non-PIT group, Mann–Whitney U-test). (D) Time course analysis of GFP fluorescence intensity in the NIR-PIT treated group. %TBRGFP only 24 and 48 h after NIR-PIT showed significant decreases in comparison with pretreatment % TBRGFP (*p < 0.05, vs pretreatment %TBRGFP, paired t-test).